Safe Cosmetics Act of 2010

-HR 5786, "Safe Cosmetics Act", regarding issues related to the regulation of cosmetics. -HR 759, "FDA Globalization Act", regarding issues related to the regulation of cosmetics.

Client expense: $280,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Postal Regulatory Commission, SENATE

- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications. - H.R. 2923, "A bill to Enhance the ability to combat Methamphetamine", regarding all provisions. - H.R. 5786, "Safe Cosmetics Act of 2010", regarding all provisions.

Client expense: $850,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of

The Implementation of the Patient Protection and Affordable Care Act; H.R. 5786, The Safe Cosmetics Act of 2010

Client expense: $980,915 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

FDA regulation of cosmetics - HR 5786, Safe Cosmetics Act of 2010; HR 759, Food and Drug Administration Globalization Act of 2009; Proposed legislation re this issue.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1020, to amend chapter 1 of title 9 of U.S. Code with respect to arbitration. H.R. 1815, to clarify the applicability of certain provisions in the Consumer Product Safety Improvement Act. H.R. 2088, to require the Food and Drug Administration to finalize a standard for broad-spectrum protection in sunscreen products. H.R. 3394, to amend the Federal Trade Commission Act concerning the burden of proof in false advertising cases involving dietary supplements and dietary ingredients. H.R. 3395, to amend the Federal Food, Drug, and Cosmetic Act concerning claims about the effects of foods and dietary supplements on health-related conditions and disease. H.R. 4173, to provide for financial regulatory reform, to protect consumers and investors, to enhance federal understanding of insurance issues, to regulate the over-the-counter derivatives markets, and for other purposes. H.R. 5777, to foster transparency about the commercial use of personal information, provide consumers with meaningful choice about the collection, use, and disclosure of such information. H.R. 5786, to amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the safe use of cosmetics. S. 710, to prohibit unfair or deceptive acts or practices relating to gift certificates, store gift cards, and other general-use prepaid cards, and for other purposes. S. 925, to direct the secretary of health and human services to study the presence of contaminants and impurities in cosmetics and personal care products marketed to and used by children. S. 1112, to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $40,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

H.R. 759; Food and Drug Administration Globalization Act of 2009; Title III (Cosmetic Safety). H.R. 5786; Safe Cosmetics Act of 2010; entire bill. S. 510; FDA Food Safety Modernization Act; proposed amendment concerning Bisphenol-A.

Client expense: $50,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)

In legislation to reform the Toxic Substances Control Act (TSCA), including H.R. 5820, the Toxic Chemicals Safety Act, and S. 3209, the Safe Chemicals Act, seeking inclusion of language to modernize testing methods for industrial chemicals and reduce reliance on inefficient, outdated, and unreliable animal-based testing methods. Seeking similar language included in a related bill, H.R. 5786, the Safe Cosmetics Act of 2010.

Client expense: $113,592 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Food and import safety legislation, HR 759, the FDA Globalization Act and S510, FDA Food Safety Modernization Act, provisions related to cosmetics. S3209, Safe Chemicals Act of 2010 and H.R. 5820, Toxic Chemicals Safety Act of 2010, provisions related to ingredients regulated by FDA and EPA. H.R. 5786, Safe Cosmetics Act of 2010, all provisions.

Client expense: Not reported · Firm income: $20,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1020, to amend chapter 1 of title 9 of U.S. Code with respect to arbitration. H.R. 1815, to clarify the applicability of certain provisions in the Consumer Product Safety Improvement Act. H.R. 2088, to require the Food and Drug Administration to finalize a standard for broad-spectrum protection in sunscreen products. H.R. 3394, to amend the Federal Trade Commission Act concerning the burden of proof in false advertising cases involving dietary supplements and dietary ingredients. H.R. 3395, to amend the Federal Food, Drug, and Cosmetic Act concerning claims about the effects of foods and dietary supplements on health-related conditions and disease. H.R. 4173, to provide for financial regulatory reform, to protect consumers and investors, to enhance federal understanding of insurance issues, to regulate the over-the-counter derivatives markets, and for other purposes. H.R. 5777, to foster transparency about the commercial use of personal information, provide consumers with meaningful choice about the collection, use, and disclosure of such information. H.R. 5786, to amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the safe use of cosmetics. S. 710, to prohibit unfair or deceptive acts or practices relating to gift certificates, store gift cards, and other general-use prepaid cards, and for other purposes. S. 925, to direct the secretary of health and human services to study the presence of contaminants and impurities in cosmetics and personal care products marketed to and used by children. S. 1112, to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

HR 759, FDA Globalization Act - provisions related to the regulation of cosmetics; S 510, Food Saftey Modernization Act - provisions related to cosmetics; S 3209, Safe Chemicals Act of 2010 - provisions related to ingredients regulated by FDA and EPA; HR 5820, Toxic Chemicals Safety Act of 2010 - provisions related to ingredients regulated by FDA and EPA; HR 5786, Safe Cosmetics Act of 2010

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 759; Food and Drug Administration Globalization Act of 2009; Title III (Cosmetic Safety). H.R. 5786; Safe Cosmetics Act of 2010; entire bill. S. 510; FDA Food Safety Modernization Act; proposed amendment concerning Bisphenol-A.

Client expense: $140,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)

The Implementation of the Patient Protection and Affordable Care Act; H.R. 5786, The Safe Cosmetics Act of 2010

Client expense: $1,030,211 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

-HR 5786, "Safe Cosmetics Act", regarding issues related to the regulation of cosmetics. -HR 759, "FDA Globalization Act", regarding issues related to the regulation of cosmetics.

Client expense: $280,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $40,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications. - H.R. 2923, "A bill to Enhance the ability to combat Methamphetimine", regarding all provisions. - H.R. 5786, "Safe Cosmetics Act of 2010", regarding all provisions.

Client expense: $2,410,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of

Toxic Substances Control Act reform (S. 3209 and H.R. 5820); Legislation on endocrine disruptors (H.R. 4190, S. 2828, H.R. 5320, H.R. 5210); Safe Cosmetic Act (H.R. 5786); House investigation into fluids used in hydraulic fracturing ("fracking") process.

Client expense: $290,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Chemical reform and product safety issues; H.R. 5786, SAFE Cosmetics Act

Client expense: Not reported · Firm income: $190,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA regulation of cosmetics - HR 5786, Safe Cosmetics Act of 2010; HR 759, Food and Drug Administration Globalization Act of 2009; Proposed legislation re this issue.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 5786 - Safe Cosmetics Act of 2010 Senate Bill still being drafted All sections particularly the safety standard, labeling, registration and prioritization provisions.

Client expense: $41,243 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE

Food and import safety legislation, HR 759, the FDA Globalization Act and S510, FDA Food Safety Modernization Act, provisions related to cosmetics. S3209, Safe Chemicals Act of 2010 and H.R. 5820, Toxic Chemicals Safety Act of 2010, provisions related to ingredients regulated by FDA and EPA. H.R. 5786, Safe Cosmetics Act of 2010, all provisions.

Client expense: Not reported · Firm income: $20,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.5786 -- Safe Cosmetics Act of 2010

Client expense: $8,346 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Oceanic & Atmospheric Administration (NOAA), SENATE